Perspective Therapeutics, Inc. (CATX)
3.13
+0.01
(+0.32%)
USD |
NYAM |
Sep 04, 16:00
3.145
+0.02
(+0.48%)
Pre-Market: 20:00
Perspective Therapeutics Research and Development Expense (Quarterly) : 20.40M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.40M |
| March 31, 2026 | 20.25M |
| December 31, 2025 | 21.91M |
| September 30, 2025 | 19.56M |
| June 30, 2025 | 15.89M |
| March 31, 2025 | 13.60M |
| December 31, 2024 | 12.17M |
| September 30, 2024 | 11.36M |
| June 30, 2024 | 9.275M |
| March 31, 2024 | 7.452M |
| September 30, 2023 | 5.353M |
| June 30, 2023 | 5.37M |
| March 31, 2023 | 3.309M |
| June 30, 2022 | 0.796M |
| March 31, 2022 | 0.549M |
| December 31, 2021 | 0.535M |
| September 30, 2021 | 0.702M |
| June 30, 2021 | 0.468M |
| March 31, 2021 | 0.362M |
| December 31, 2020 | 0.285M |
| September 30, 2020 | 0.312M |
| June 30, 2020 | 0.322M |
| March 31, 2020 | 0.294M |
| December 31, 2019 | 0.277M |
| September 30, 2019 | 0.233M |
| Date | Value |
|---|---|
| June 30, 2019 | 0.341M |
| March 31, 2019 | 0.299M |
| December 31, 2018 | 0.414M |
| September 30, 2018 | 0.42M |
| June 30, 2018 | 0.572M |
| March 31, 2018 | 0.473M |
| December 31, 2017 | 0.34M |
| September 30, 2017 | 0.362M |
| June 30, 2017 | 0.316M |
| March 31, 2017 | 0.327M |
| December 31, 2016 | 0.15M |
| September 30, 2016 | 0.172M |
| June 30, 2016 | 0.1427M |
| March 31, 2016 | 0.1832M |
| December 31, 2015 | 0.0582M |
| September 30, 2015 | 0.1439M |
| June 30, 2015 | 0.1561M |
| March 31, 2015 | 0.1414M |
| December 31, 2014 | 0.1406M |
| September 30, 2014 | 0.1766M |
| June 30, 2014 | 0.1982M |
| March 31, 2014 | 0.1536M |
| December 31, 2013 | 0.17M |
| September 30, 2013 | 0.147M |
| June 30, 2013 | 0.1813M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 7.341M |
| MiMedx Group, Inc. | 2.777M |
| ABVC BioPharma, Inc. | 0.0227M |
| Enovis Corp. | 31.69M |
| Edwards Lifesciences Corp. | 278.90M |